|Bid||8.70 x 1200|
|Ask||9.00 x 1000|
|Day's Range||8.40 - 9.00|
|52 Week Range||3.80 - 10.40|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.80|
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classifier for evaluating indeterminate thyroid nodules retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR® from approximately $1800 to $3000 reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices. Today, approximately 30% of the Company’s ThyraMIR® volume is attributable to Medicare eligible patients.
Ron Rocca, CEO of Exagen, appointed to BoardJames Early, CFO announces retirement; Fred Knechtel, formerly CFO of GENEWIZ, appointed as CFOJeff Salzman, formerly of CareDX,.
1315 Capital and Ampersand are two leading private equity firms investing in laboratory services. The new Series B Preferred Stock investment will be convertible into common stock at a conversion price of $0.60 (prior to the reverse stock split).
Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, Interpace Diagnostics has entered into a collaborative study aimed at exploring the potential use of BarreGEN® in patients undergoing radiofrequency ablation (RFA). RFA is typically known as a cancer preventative therapy that either delays or arrests the progression of Barrett’s Esophagus to esophageal cancer. Evidence to date suggests that BarreGEN® may identify non-dysplastic Barrett’s Esophagus patients in need of ablation, making targeted ablation a potentially cost-effective treatment option.
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT® test, representing an increase of approximately $2,400 per assay over previous reimbursement coverage. In 2018, Interpace processed approximately 12,500 ThyGeNEXT® tests.
Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (PRC). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC.
Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented together on one easy to navigate website. The site provides information on the offerings of both divisions including diagnostic and tailored laboratory services testing, patient support, physician education, clinical trial data management, project management, and bioinformatics.
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew.
Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and provide a general business update. A webcast replay will be available on the company’s website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the company’s website for 90 days.
Interpace Group (IDXG) Interpace Diagnostics announced today the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT® when used alone and in combination with ThyraMIR®. The most recent article was published in Diagnostic Cytopathology in a paper called “Incremental Utility of Expanded Mutation Panel When Used in Combination with MicroRNA Classification in Indeterminate Thyroid Nodules”. The study is now published on the Diagnostic Cytopathology website at https://doi.org/10.1002/dc.24328 and compares results of ThyGenX®, Interpace’s first-generation mutation panel, with ThyGeNEXT®, Interpace’s expanded second-generation mutation panel, showing that the expanded panel provides additional utility when used in combination with ThyraMIR®, Interpace’s microRNA risk classifier.
Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA), being held October 30th to November 3rd, 2019 in Chicago, IL. The ATA meeting is one of the largest gatherings of endocrinologists, ENT’s, surgeons and other providers who focus on the diagnosis and treatment of thyroid cancer.
Cancer Genetics, Inc. (CGIX), a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today announced, among others, the completion of several strategic transactions. As the result of the previously announced sale of the company’s BioPharma business to Interpace Diagnostics Group, Inc. (IDXG) or its affiliate, IDXG or its affiliate paid approximately $6 million in cash to CGIX on October 24, 2019, as partial settlement of a promissory note in the original face amount of approximately $7.7 million due to CGIX.
Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid and GI products at an industry known scientific international meeting. The American College of Gastroenterology annual meeting is held on October 27-30 in San Antonio, Texas and is one of the largest gatherings of gastroenterologists and endoscopists. The PancraGEN publication entitled “Serial molecular testing of pancreatic cyst fluid over time: progression and regression” highlights the Company’s unique clinical and molecular database of patient results, examining 2,167 patients with pancreatic cysts that underwent multiple PancraGEN tests over time.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019.
The big shareholder groups in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) have power over the company...
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review’s editorial board recognizing companies whose industry achievements break new technological ground and who’s company cultures and values represent a commitment to innovation. “We are pleased to be recognized by The Silicon Review as one of the 50 Most Admired Companies as we continue to push the envelope in providing diagnostic tests and biopharma services to help assess the risk of cancer progression and select the best treatment for patients”, said Jack Stover, CEO of Interpace.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has contracted with 3 independent Blue Cross Blue Shield (BCBS) plans totaling nearly 5 million covered lives across Alabama, Arkansas, and Arizona. The ThyGeNEXT® - ThyraMIR® combination represents the first and only test on the market that includes the rule-out properties of next-generation sequencing of a patient’s DNA and RNA along with the rule-in capabilities of a micro-RNA classifier to provide physicians with clinically actionable test results. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades.
PARSIPPANY, NJ, Sept. 18, 2019 -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming.
Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC.
PARSIPPANY, NJ, Sept. 06, 2019 -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming.
MINNEAPOLIS, Aug. 19, 2019 -- Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased.
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...